Drug Type Oligonucleotide |
Synonyms E2F decoy ODN, E2F duplex decoy, E2F transcription factor decoy + [7] |
Target |
Mechanism E2F1 inhibitors(Transcription factor E2F1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Arterial Occlusive Diseases | Phase 3 | US | 01 Nov 2001 | |
Arterial Occlusive Diseases | Phase 3 | CA | 01 Nov 2001 | |
Graft Occlusion, Vascular | Phase 3 | US | 01 Nov 2001 | |
Graft Occlusion, Vascular | Phase 3 | CA | 01 Nov 2001 | |
Hyperplasia | Phase 3 | US | 01 Nov 2001 | |
Hyperplasia | Phase 3 | CA | 01 Nov 2001 | |
Ischemia | Phase 3 | US | 01 Nov 2001 | |
Ischemia | Phase 3 | CA | 01 Nov 2001 | |
Peripheral Vascular Diseases | Phase 3 | US | 01 Nov 2001 | |
Peripheral Vascular Diseases | Phase 3 | CA | 01 Nov 2001 |
Phase 3 | - | - | dudxjqqjmx(lqmrqaiyep) = zkgqtnhzbj sgtenvldjy (ysutjbrgqc ) View more | - | 01 Sep 2012 | ||
Placebo | dudxjqqjmx(lqmrqaiyep) = mposipckiz sgtenvldjy (ysutjbrgqc ) View more | ||||||
Phase 3 | 3,014 | oprcpvfsrk(wdonsrwdql) = vmnjcxnwrj mfiqcujfvr (hnamrtqlsq ) View more | Negative | 16 Nov 2005 | |||
Placebo | oprcpvfsrk(wdonsrwdql) = wjaztxdxwh mfiqcujfvr (hnamrtqlsq ) View more |